Global Recombinant DNA Vaccine Market Research Report 2023
Recombinant DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines.
According to QYResearch’s new survey, global Recombinant DNA Vaccine market is projected to reach US$ 502.8 million in 2029, increasing from US$ 186 million in 2022, with the CAGR of 15.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant DNA Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant DNA Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
According to QYResearch’s new survey, global Recombinant DNA Vaccine market is projected to reach US$ 502.8 million in 2029, increasing from US$ 186 million in 2022, with the CAGR of 15.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant DNA Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Recombinant DNA Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- Merck
- GSK
- Sanofi
- Zoties
- Elanco
- Boehringer-Ingelheim
- Indian Immunologicals
- Plumbline Life Sciences
- Recombinant Protein Vaccine
- Gene-Based Vaccine
- Human
- Animal
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
1 RECOMBINANT DNA VACCINE MARKET OVERVIEW
1.1 Product Overview and Scope of Recombinant DNA Vaccine
1.2 Recombinant DNA Vaccine Segment by Type
1.2.1 Global Recombinant DNA Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Recombinant Protein Vaccine
1.2.3 Gene-Based Vaccine
1.3 Recombinant DNA Vaccine Segment by Application
1.3.1 Global Recombinant DNA Vaccine Market Value by Application: (2023-2029)
1.3.2 Human
1.3.3 Animal
1.4 Global Recombinant DNA Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant DNA Vaccine Revenue 2018-2029
1.4.2 Global Recombinant DNA Vaccine Sales 2018-2029
1.4.3 Global Recombinant DNA Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 RECOMBINANT DNA VACCINE MARKET COMPETITION BY MANUFACTURERS
2.1 Global Recombinant DNA Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant DNA Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant DNA Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant DNA Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant DNA Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant DNA Vaccine, Product Type & Application
2.7 Recombinant DNA Vaccine Market Competitive Situation and Trends
2.7.1 Recombinant DNA Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant DNA Vaccine Players Market Share by Revenue
2.7.3 Global Recombinant DNA Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 RECOMBINANT DNA VACCINE RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Recombinant DNA Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant DNA Vaccine Global Recombinant DNA Vaccine Sales by Region: 2018-2029
3.2.1 Global Recombinant DNA Vaccine Sales by Region: 2018-2023
3.2.2 Global Recombinant DNA Vaccine Sales by Region: 2024-2029
3.3 Global Recombinant DNA Vaccine Global Recombinant DNA Vaccine Revenue by Region: 2018-2029
3.3.1 Global Recombinant DNA Vaccine Revenue by Region: 2018-2023
3.3.2 Global Recombinant DNA Vaccine Revenue by Region: 2024-2029
3.4 North America Recombinant DNA Vaccine Market Facts & Figures by Country
3.4.1 North America Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant DNA Vaccine Sales by Country (2018-2029)
3.4.3 North America Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant DNA Vaccine Market Facts & Figures by Country
3.5.1 Europe Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant DNA Vaccine Sales by Country (2018-2029)
3.5.3 Europe Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant DNA Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant DNA Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Recombinant DNA Vaccine Market Facts & Figures by Country
3.7.1 Latin America Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant DNA Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant DNA Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant DNA Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Recombinant DNA Vaccine Sales by Type (2018-2029)
4.1.1 Global Recombinant DNA Vaccine Sales by Type (2018-2023)
4.1.2 Global Recombinant DNA Vaccine Sales by Type (2024-2029)
4.1.3 Global Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Recombinant DNA Vaccine Revenue by Type (2018-2029)
4.2.1 Global Recombinant DNA Vaccine Revenue by Type (2018-2023)
4.2.2 Global Recombinant DNA Vaccine Revenue by Type (2024-2029)
4.2.3 Global Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant DNA Vaccine Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Recombinant DNA Vaccine Sales by Application (2018-2029)
5.1.1 Global Recombinant DNA Vaccine Sales by Application (2018-2023)
5.1.2 Global Recombinant DNA Vaccine Sales by Application (2024-2029)
5.1.3 Global Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Recombinant DNA Vaccine Revenue by Application (2018-2029)
5.2.1 Global Recombinant DNA Vaccine Revenue by Application (2018-2023)
5.2.2 Global Recombinant DNA Vaccine Revenue by Application (2024-2029)
5.2.3 Global Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant DNA Vaccine Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Recombinant DNA Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Recombinant DNA Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Recombinant DNA Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Zoties
6.4.1 Zoties Corporation Information
6.4.2 Zoties Description and Business Overview
6.4.3 Zoties Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Zoties Recombinant DNA Vaccine Product Portfolio
6.4.5 Zoties Recent Developments/Updates
6.5 Elanco
6.5.1 Elanco Corporation Information
6.5.2 Elanco Description and Business Overview
6.5.3 Elanco Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Elanco Recombinant DNA Vaccine Product Portfolio
6.5.5 Elanco Recent Developments/Updates
6.6 Boehringer-Ingelheim
6.6.1 Boehringer-Ingelheim Corporation Information
6.6.2 Boehringer-Ingelheim Description and Business Overview
6.6.3 Boehringer-Ingelheim Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Boehringer-Ingelheim Recombinant DNA Vaccine Product Portfolio
6.6.5 Boehringer-Ingelheim Recent Developments/Updates
6.7 Indian Immunologicals
6.6.1 Indian Immunologicals Corporation Information
6.6.2 Indian Immunologicals Description and Business Overview
6.6.3 Indian Immunologicals Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Indian Immunologicals Recombinant DNA Vaccine Product Portfolio
6.7.5 Indian Immunologicals Recent Developments/Updates
6.8 Plumbline Life Sciences
6.8.1 Plumbline Life Sciences Corporation Information
6.8.2 Plumbline Life Sciences Description and Business Overview
6.8.3 Plumbline Life Sciences Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Plumbline Life Sciences Recombinant DNA Vaccine Product Portfolio
6.8.5 Plumbline Life Sciences Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Recombinant DNA Vaccine Industry Chain Analysis
7.2 Recombinant DNA Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant DNA Vaccine Production Mode & Process
7.4 Recombinant DNA Vaccine Sales and Marketing
7.4.1 Recombinant DNA Vaccine Sales Channels
7.4.2 Recombinant DNA Vaccine Distributors
7.5 Recombinant DNA Vaccine Customers
8 RECOMBINANT DNA VACCINE MARKET DYNAMICS
8.1 Recombinant DNA Vaccine Industry Trends
8.2 Recombinant DNA Vaccine Market Drivers
8.3 Recombinant DNA Vaccine Market Challenges
8.4 Recombinant DNA Vaccine Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Recombinant DNA Vaccine
1.2 Recombinant DNA Vaccine Segment by Type
1.2.1 Global Recombinant DNA Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Recombinant Protein Vaccine
1.2.3 Gene-Based Vaccine
1.3 Recombinant DNA Vaccine Segment by Application
1.3.1 Global Recombinant DNA Vaccine Market Value by Application: (2023-2029)
1.3.2 Human
1.3.3 Animal
1.4 Global Recombinant DNA Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant DNA Vaccine Revenue 2018-2029
1.4.2 Global Recombinant DNA Vaccine Sales 2018-2029
1.4.3 Global Recombinant DNA Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 RECOMBINANT DNA VACCINE MARKET COMPETITION BY MANUFACTURERS
2.1 Global Recombinant DNA Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Recombinant DNA Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Recombinant DNA Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Recombinant DNA Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Recombinant DNA Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant DNA Vaccine, Product Type & Application
2.7 Recombinant DNA Vaccine Market Competitive Situation and Trends
2.7.1 Recombinant DNA Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant DNA Vaccine Players Market Share by Revenue
2.7.3 Global Recombinant DNA Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 RECOMBINANT DNA VACCINE RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Recombinant DNA Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Recombinant DNA Vaccine Global Recombinant DNA Vaccine Sales by Region: 2018-2029
3.2.1 Global Recombinant DNA Vaccine Sales by Region: 2018-2023
3.2.2 Global Recombinant DNA Vaccine Sales by Region: 2024-2029
3.3 Global Recombinant DNA Vaccine Global Recombinant DNA Vaccine Revenue by Region: 2018-2029
3.3.1 Global Recombinant DNA Vaccine Revenue by Region: 2018-2023
3.3.2 Global Recombinant DNA Vaccine Revenue by Region: 2024-2029
3.4 North America Recombinant DNA Vaccine Market Facts & Figures by Country
3.4.1 North America Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Recombinant DNA Vaccine Sales by Country (2018-2029)
3.4.3 North America Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant DNA Vaccine Market Facts & Figures by Country
3.5.1 Europe Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Recombinant DNA Vaccine Sales by Country (2018-2029)
3.5.3 Europe Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant DNA Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Recombinant DNA Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Recombinant DNA Vaccine Market Facts & Figures by Country
3.7.1 Latin America Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Recombinant DNA Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant DNA Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant DNA Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Recombinant DNA Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Recombinant DNA Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Recombinant DNA Vaccine Sales by Type (2018-2029)
4.1.1 Global Recombinant DNA Vaccine Sales by Type (2018-2023)
4.1.2 Global Recombinant DNA Vaccine Sales by Type (2024-2029)
4.1.3 Global Recombinant DNA Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Recombinant DNA Vaccine Revenue by Type (2018-2029)
4.2.1 Global Recombinant DNA Vaccine Revenue by Type (2018-2023)
4.2.2 Global Recombinant DNA Vaccine Revenue by Type (2024-2029)
4.2.3 Global Recombinant DNA Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant DNA Vaccine Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Recombinant DNA Vaccine Sales by Application (2018-2029)
5.1.1 Global Recombinant DNA Vaccine Sales by Application (2018-2023)
5.1.2 Global Recombinant DNA Vaccine Sales by Application (2024-2029)
5.1.3 Global Recombinant DNA Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Recombinant DNA Vaccine Revenue by Application (2018-2029)
5.2.1 Global Recombinant DNA Vaccine Revenue by Application (2018-2023)
5.2.2 Global Recombinant DNA Vaccine Revenue by Application (2024-2029)
5.2.3 Global Recombinant DNA Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant DNA Vaccine Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Recombinant DNA Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Recombinant DNA Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Recombinant DNA Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Zoties
6.4.1 Zoties Corporation Information
6.4.2 Zoties Description and Business Overview
6.4.3 Zoties Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Zoties Recombinant DNA Vaccine Product Portfolio
6.4.5 Zoties Recent Developments/Updates
6.5 Elanco
6.5.1 Elanco Corporation Information
6.5.2 Elanco Description and Business Overview
6.5.3 Elanco Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Elanco Recombinant DNA Vaccine Product Portfolio
6.5.5 Elanco Recent Developments/Updates
6.6 Boehringer-Ingelheim
6.6.1 Boehringer-Ingelheim Corporation Information
6.6.2 Boehringer-Ingelheim Description and Business Overview
6.6.3 Boehringer-Ingelheim Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Boehringer-Ingelheim Recombinant DNA Vaccine Product Portfolio
6.6.5 Boehringer-Ingelheim Recent Developments/Updates
6.7 Indian Immunologicals
6.6.1 Indian Immunologicals Corporation Information
6.6.2 Indian Immunologicals Description and Business Overview
6.6.3 Indian Immunologicals Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Indian Immunologicals Recombinant DNA Vaccine Product Portfolio
6.7.5 Indian Immunologicals Recent Developments/Updates
6.8 Plumbline Life Sciences
6.8.1 Plumbline Life Sciences Corporation Information
6.8.2 Plumbline Life Sciences Description and Business Overview
6.8.3 Plumbline Life Sciences Recombinant DNA Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Plumbline Life Sciences Recombinant DNA Vaccine Product Portfolio
6.8.5 Plumbline Life Sciences Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Recombinant DNA Vaccine Industry Chain Analysis
7.2 Recombinant DNA Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant DNA Vaccine Production Mode & Process
7.4 Recombinant DNA Vaccine Sales and Marketing
7.4.1 Recombinant DNA Vaccine Sales Channels
7.4.2 Recombinant DNA Vaccine Distributors
7.5 Recombinant DNA Vaccine Customers
8 RECOMBINANT DNA VACCINE MARKET DYNAMICS
8.1 Recombinant DNA Vaccine Industry Trends
8.2 Recombinant DNA Vaccine Market Drivers
8.3 Recombinant DNA Vaccine Market Challenges
8.4 Recombinant DNA Vaccine Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
LIST OF TABLES
Table 1. Global Recombinant DNA Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Recombinant DNA Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Recombinant DNA Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Recombinant DNA Vaccine Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Recombinant DNA Vaccine Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Recombinant DNA Vaccine Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Recombinant DNA Vaccine Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Recombinant DNA Vaccine Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Recombinant DNA Vaccine, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Recombinant DNA Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Recombinant DNA Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Recombinant DNA Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Recombinant DNA Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant DNA Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant DNA Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Recombinant DNA Vaccine Sales by Region (2018-2023) & (K Units)
Table 18. Global Recombinant DNA Vaccine Sales Market Share by Region (2018-2023)
Table 19. Global Recombinant DNA Vaccine Sales by Region (2024-2029) & (K Units)
Table 20. Global Recombinant DNA Vaccine Sales Market Share by Region (2024-2029)
Table 21. Global Recombinant DNA Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Recombinant DNA Vaccine Revenue Market Share by Region (2018-2023)
Table 23. Global Recombinant DNA Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Recombinant DNA Vaccine Revenue Market Share by Region (2024-2029)
Table 25. North America Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Recombinant DNA Vaccine Sales by Country (2018-2023) & (K Units)
Table 27. North America Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 28. North America Recombinant DNA Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Recombinant DNA Vaccine Sales by Country (2018-2023) & (K Units)
Table 32. Europe Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 33. Europe Recombinant DNA Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Recombinant DNA Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Recombinant DNA Vaccine Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Recombinant DNA Vaccine Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Recombinant DNA Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Recombinant DNA Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Recombinant DNA Vaccine Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Recombinant DNA Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Recombinant DNA Vaccine Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Recombinant DNA Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Recombinant DNA Vaccine Sales (K Units) by Type (2018-2023)
Table 51. Global Recombinant DNA Vaccine Sales (K Units) by Type (2024-2029)
Table 52. Global Recombinant DNA Vaccine Sales Market Share by Type (2018-2023)
Table 53. Global Recombinant DNA Vaccine Sales Market Share by Type (2024-2029)
Table 54. Global Recombinant DNA Vaccine Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Recombinant DNA Vaccine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Recombinant DNA Vaccine Revenue Market Share by Type (2018-2023)
Table 57. Global Recombinant DNA Vaccine Revenue Market Share by Type (2024-2029)
Table 58. Global Recombinant DNA Vaccine Price (US$/Unit) by Type (2018-2023)
Table 59. Global Recombinant DNA Vaccine Price (US$/Unit) by Type (2024-2029)
Table 60. Global Recombinant DNA Vaccine Sales (K Units) by Application (2018-2023)
Table 61. Global Recombinant DNA Vaccine Sales (K Units) by Application (2024-2029)
Table 62. Global Recombinant DNA Vaccine Sales Market Share by Application (2018-2023)
Table 63. Global Recombinant DNA Vaccine Sales Market Share by Application (2024-2029)
Table 64. Global Recombinant DNA Vaccine Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Recombinant DNA Vaccine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Recombinant DNA Vaccine Revenue Market Share by Application (2018-2023)
Table 67. Global Recombinant DNA Vaccine Revenue Market Share by Application (2024-2029)
Table 68. Global Recombinant DNA Vaccine Price (US$/Unit) by Application (2018-2023)
Table 69. Global Recombinant DNA Vaccine Price (US$/Unit) by Application (2024-2029)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Merck Recombinant DNA Vaccine Product
Table 74. Merck Recent Developments/Updates
Table 75. GSK Corporation Information
Table 76. GSK Description and Business Overview
Table 77. GSK Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. GSK Recombinant DNA Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Sanofi Corporation Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Sanofi Recombinant DNA Vaccine Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Zoties Corporation Information
Table 86. Zoties Description and Business Overview
Table 87. Zoties Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Zoties Recombinant DNA Vaccine Product
Table 89. Zoties Recent Developments/Updates
Table 90. Elanco Corporation Information
Table 91. Elanco Description and Business Overview
Table 92. Elanco Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Elanco Recombinant DNA Vaccine Product
Table 94. Elanco Recent Developments/Updates
Table 95. Boehringer-Ingelheim Corporation Information
Table 96. Boehringer-Ingelheim Description and Business Overview
Table 97. Boehringer-Ingelheim Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Boehringer-Ingelheim Recombinant DNA Vaccine Product
Table 99. Boehringer-Ingelheim Recent Developments/Updates
Table 100. Indian Immunologicals Corporation Information
Table 101. Indian Immunologicals Description and Business Overview
Table 102. Indian Immunologicals Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Indian Immunologicals Recombinant DNA Vaccine Product
Table 104. Indian Immunologicals Recent Developments/Updates
Table 105. Plumbline Life Sciences Corporation Information
Table 106. Plumbline Life Sciences Description and Business Overview
Table 107. Plumbline Life Sciences Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Plumbline Life Sciences Recombinant DNA Vaccine Product
Table 109. Plumbline Life Sciences Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Recombinant DNA Vaccine Distributors List
Table 113. Recombinant DNA Vaccine Customers List
Table 114. Recombinant DNA Vaccine Market Trends
Table 115. Recombinant DNA Vaccine Market Drivers
Table 116. Recombinant DNA Vaccine Market Challenges
Table 117. Recombinant DNA Vaccine Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 1. Global Recombinant DNA Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Recombinant DNA Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Recombinant DNA Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Recombinant DNA Vaccine Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Recombinant DNA Vaccine Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Recombinant DNA Vaccine Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Recombinant DNA Vaccine Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Recombinant DNA Vaccine Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Recombinant DNA Vaccine, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Recombinant DNA Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Recombinant DNA Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Recombinant DNA Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Recombinant DNA Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant DNA Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant DNA Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Recombinant DNA Vaccine Sales by Region (2018-2023) & (K Units)
Table 18. Global Recombinant DNA Vaccine Sales Market Share by Region (2018-2023)
Table 19. Global Recombinant DNA Vaccine Sales by Region (2024-2029) & (K Units)
Table 20. Global Recombinant DNA Vaccine Sales Market Share by Region (2024-2029)
Table 21. Global Recombinant DNA Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Recombinant DNA Vaccine Revenue Market Share by Region (2018-2023)
Table 23. Global Recombinant DNA Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Recombinant DNA Vaccine Revenue Market Share by Region (2024-2029)
Table 25. North America Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Recombinant DNA Vaccine Sales by Country (2018-2023) & (K Units)
Table 27. North America Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 28. North America Recombinant DNA Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Recombinant DNA Vaccine Sales by Country (2018-2023) & (K Units)
Table 32. Europe Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 33. Europe Recombinant DNA Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Recombinant DNA Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Recombinant DNA Vaccine Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Recombinant DNA Vaccine Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Recombinant DNA Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Recombinant DNA Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Recombinant DNA Vaccine Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Recombinant DNA Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Recombinant DNA Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Recombinant DNA Vaccine Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Recombinant DNA Vaccine Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Recombinant DNA Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Recombinant DNA Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Recombinant DNA Vaccine Sales (K Units) by Type (2018-2023)
Table 51. Global Recombinant DNA Vaccine Sales (K Units) by Type (2024-2029)
Table 52. Global Recombinant DNA Vaccine Sales Market Share by Type (2018-2023)
Table 53. Global Recombinant DNA Vaccine Sales Market Share by Type (2024-2029)
Table 54. Global Recombinant DNA Vaccine Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Recombinant DNA Vaccine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Recombinant DNA Vaccine Revenue Market Share by Type (2018-2023)
Table 57. Global Recombinant DNA Vaccine Revenue Market Share by Type (2024-2029)
Table 58. Global Recombinant DNA Vaccine Price (US$/Unit) by Type (2018-2023)
Table 59. Global Recombinant DNA Vaccine Price (US$/Unit) by Type (2024-2029)
Table 60. Global Recombinant DNA Vaccine Sales (K Units) by Application (2018-2023)
Table 61. Global Recombinant DNA Vaccine Sales (K Units) by Application (2024-2029)
Table 62. Global Recombinant DNA Vaccine Sales Market Share by Application (2018-2023)
Table 63. Global Recombinant DNA Vaccine Sales Market Share by Application (2024-2029)
Table 64. Global Recombinant DNA Vaccine Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Recombinant DNA Vaccine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Recombinant DNA Vaccine Revenue Market Share by Application (2018-2023)
Table 67. Global Recombinant DNA Vaccine Revenue Market Share by Application (2024-2029)
Table 68. Global Recombinant DNA Vaccine Price (US$/Unit) by Application (2018-2023)
Table 69. Global Recombinant DNA Vaccine Price (US$/Unit) by Application (2024-2029)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Merck Recombinant DNA Vaccine Product
Table 74. Merck Recent Developments/Updates
Table 75. GSK Corporation Information
Table 76. GSK Description and Business Overview
Table 77. GSK Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. GSK Recombinant DNA Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Sanofi Corporation Information
Table 81. Sanofi Description and Business Overview
Table 82. Sanofi Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Sanofi Recombinant DNA Vaccine Product
Table 84. Sanofi Recent Developments/Updates
Table 85. Zoties Corporation Information
Table 86. Zoties Description and Business Overview
Table 87. Zoties Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Zoties Recombinant DNA Vaccine Product
Table 89. Zoties Recent Developments/Updates
Table 90. Elanco Corporation Information
Table 91. Elanco Description and Business Overview
Table 92. Elanco Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Elanco Recombinant DNA Vaccine Product
Table 94. Elanco Recent Developments/Updates
Table 95. Boehringer-Ingelheim Corporation Information
Table 96. Boehringer-Ingelheim Description and Business Overview
Table 97. Boehringer-Ingelheim Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Boehringer-Ingelheim Recombinant DNA Vaccine Product
Table 99. Boehringer-Ingelheim Recent Developments/Updates
Table 100. Indian Immunologicals Corporation Information
Table 101. Indian Immunologicals Description and Business Overview
Table 102. Indian Immunologicals Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Indian Immunologicals Recombinant DNA Vaccine Product
Table 104. Indian Immunologicals Recent Developments/Updates
Table 105. Plumbline Life Sciences Corporation Information
Table 106. Plumbline Life Sciences Description and Business Overview
Table 107. Plumbline Life Sciences Recombinant DNA Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Plumbline Life Sciences Recombinant DNA Vaccine Product
Table 109. Plumbline Life Sciences Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Recombinant DNA Vaccine Distributors List
Table 113. Recombinant DNA Vaccine Customers List
Table 114. Recombinant DNA Vaccine Market Trends
Table 115. Recombinant DNA Vaccine Market Drivers
Table 116. Recombinant DNA Vaccine Market Challenges
Table 117. Recombinant DNA Vaccine Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Product Picture of Recombinant DNA Vaccine
Figure 2. Global Recombinant DNA Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Recombinant DNA Vaccine Market Share by Type in 2022 & 2029
Figure 4. Recombinant Protein Vaccine Product Picture
Figure 5. Gene-Based Vaccine Product Picture
Figure 6. Global Recombinant DNA Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Recombinant DNA Vaccine Market Share by Application in 2022 & 2029
Figure 8. Human
Figure 9. Animal
Figure 10. Global Recombinant DNA Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 11. Global Recombinant DNA Vaccine Market Size (2018-2029) & (US$ Million)
Figure 12. Global Recombinant DNA Vaccine Sales (2018-2029) & (K Units)
Figure 13. Global Recombinant DNA Vaccine Average Price (US$/Unit) & (2018-2029)
Figure 14. Recombinant DNA Vaccine Report Years Considered
Figure 15. Recombinant DNA Vaccine Sales Share by Manufacturers in 2022
Figure 16. Global Recombinant DNA Vaccine Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Recombinant DNA Vaccine Players: Market Share by Revenue in 2022
Figure 18. Recombinant DNA Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 19. Global Recombinant DNA Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 20. North America Recombinant DNA Vaccine Sales Market Share by Country (2018-2029)
Figure 21. North America Recombinant DNA Vaccine Revenue Market Share by Country (2018-2029)
Figure 22. United States Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 23. Canada Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Europe Recombinant DNA Vaccine Sales Market Share by Country (2018-2029)
Figure 25. Europe Recombinant DNA Vaccine Revenue Market Share by Country (2018-2029)
Figure 26. Germany Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. France Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. U.K. Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Italy Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Russia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Asia Pacific Recombinant DNA Vaccine Sales Market Share by Region (2018-2029)
Figure 32. Asia Pacific Recombinant DNA Vaccine Revenue Market Share by Region (2018-2029)
Figure 33. China Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Japan Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. South Korea Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. India Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Australia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. China Taiwan Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Indonesia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Thailand Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Malaysia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Latin America Recombinant DNA Vaccine Sales Market Share by Country (2018-2029)
Figure 43. Latin America Recombinant DNA Vaccine Revenue Market Share by Country (2018-2029)
Figure 44. Mexico Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Brazil Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Argentina Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Recombinant DNA Vaccine Sales Market Share by Country (2018-2029)
Figure 48. Middle East & Africa Recombinant DNA Vaccine Revenue Market Share by Country (2018-2029)
Figure 49. Turkey Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. UAE Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Global Sales Market Share of Recombinant DNA Vaccine by Type (2018-2029)
Figure 53. Global Revenue Market Share of Recombinant DNA Vaccine by Type (2018-2029)
Figure 54. Global Recombinant DNA Vaccine Price (US$/Unit) by Type (2018-2029)
Figure 55. Global Sales Market Share of Recombinant DNA Vaccine by Application (2018-2029)
Figure 56. Global Revenue Market Share of Recombinant DNA Vaccine by Application (2018-2029)
Figure 57. Global Recombinant DNA Vaccine Price (US$/Unit) by Application (2018-2029)
Figure 58. Recombinant DNA Vaccine Value Chain
Figure 59. Recombinant DNA Vaccine Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Figure 1. Product Picture of Recombinant DNA Vaccine
Figure 2. Global Recombinant DNA Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Recombinant DNA Vaccine Market Share by Type in 2022 & 2029
Figure 4. Recombinant Protein Vaccine Product Picture
Figure 5. Gene-Based Vaccine Product Picture
Figure 6. Global Recombinant DNA Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Recombinant DNA Vaccine Market Share by Application in 2022 & 2029
Figure 8. Human
Figure 9. Animal
Figure 10. Global Recombinant DNA Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 11. Global Recombinant DNA Vaccine Market Size (2018-2029) & (US$ Million)
Figure 12. Global Recombinant DNA Vaccine Sales (2018-2029) & (K Units)
Figure 13. Global Recombinant DNA Vaccine Average Price (US$/Unit) & (2018-2029)
Figure 14. Recombinant DNA Vaccine Report Years Considered
Figure 15. Recombinant DNA Vaccine Sales Share by Manufacturers in 2022
Figure 16. Global Recombinant DNA Vaccine Revenue Share by Manufacturers in 2022
Figure 17. The Global 5 and 10 Largest Recombinant DNA Vaccine Players: Market Share by Revenue in 2022
Figure 18. Recombinant DNA Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 19. Global Recombinant DNA Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 20. North America Recombinant DNA Vaccine Sales Market Share by Country (2018-2029)
Figure 21. North America Recombinant DNA Vaccine Revenue Market Share by Country (2018-2029)
Figure 22. United States Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 23. Canada Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Europe Recombinant DNA Vaccine Sales Market Share by Country (2018-2029)
Figure 25. Europe Recombinant DNA Vaccine Revenue Market Share by Country (2018-2029)
Figure 26. Germany Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. France Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. U.K. Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Italy Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Russia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Asia Pacific Recombinant DNA Vaccine Sales Market Share by Region (2018-2029)
Figure 32. Asia Pacific Recombinant DNA Vaccine Revenue Market Share by Region (2018-2029)
Figure 33. China Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Japan Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. South Korea Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. India Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Australia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. China Taiwan Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Indonesia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Thailand Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Malaysia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Latin America Recombinant DNA Vaccine Sales Market Share by Country (2018-2029)
Figure 43. Latin America Recombinant DNA Vaccine Revenue Market Share by Country (2018-2029)
Figure 44. Mexico Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Brazil Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Argentina Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Recombinant DNA Vaccine Sales Market Share by Country (2018-2029)
Figure 48. Middle East & Africa Recombinant DNA Vaccine Revenue Market Share by Country (2018-2029)
Figure 49. Turkey Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Saudi Arabia Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. UAE Recombinant DNA Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Global Sales Market Share of Recombinant DNA Vaccine by Type (2018-2029)
Figure 53. Global Revenue Market Share of Recombinant DNA Vaccine by Type (2018-2029)
Figure 54. Global Recombinant DNA Vaccine Price (US$/Unit) by Type (2018-2029)
Figure 55. Global Sales Market Share of Recombinant DNA Vaccine by Application (2018-2029)
Figure 56. Global Revenue Market Share of Recombinant DNA Vaccine by Application (2018-2029)
Figure 57. Global Recombinant DNA Vaccine Price (US$/Unit) by Application (2018-2029)
Figure 58. Recombinant DNA Vaccine Value Chain
Figure 59. Recombinant DNA Vaccine Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
